Evidence method
Level · gp.fundamentals.debt_to_revenue
238.10% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CUE · Sep 30, 2023
Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-058838General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-371.38% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
2988.24% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-543.76% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
470.19% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
98.71% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20216/6 normalizedLevel 3Dec 31, 20216/6 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 434.15%
- Current
- 238.10%
- Delta
- -196.06%
- Previous
- -750.43%
- Current
- -371.38%
- Delta
- 379.05%
- Previous
- 5215.38%
- Current
- 2988.24%
- Delta
- -2227.15%
- Previous
- -978.08%
- Current
- -543.76%
- Delta
- 434.31%
- Previous
- 770.62%
- Current
- 470.19%
- Delta
- -300.43%
- Previous
- 147.40%
- Current
- 98.71%
- Delta
- -48.68%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CUE Fundamental State →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · CUE CASH_GENERATION_INCREASED →Transitioned To · CUE GROWTH_DECREASED →Transitioned To · CUE PROFITABILITY_INCREASED →Transitioned To · CUE R_AND_D_INTENSITY_DECREASED →Transitioned To · CUE SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.